


A Highly Atroposelective Negishi Coupling Enables the Commercial Manufacturing Process of Divarasib

Stephan Bachmann, Raphael Bigler, Dainis Kaldre, Domique Kumkli, René Lebl, David Linder, Ugo Orcel, Isabelle Prévot, Jörg Sedelmeier

F. Hoffmann-La Roche Ltd. (Grenzacherstrasse 124, Basel, Switzerland)
stephan.bachmann@roche.com

The development efforts that will result in the commercial manufacturing process of divarasib (**1**), a highly potent KRAS G12C inhibitor currently undergoing Ph III clinical trials, will be highlighted. Most prominently, our process landmarks the first example of a highly atroposelective Negishi coupling at manufacturing scale, allowing isolation of the step product (*R_a*)-**4** as a single isomer without chromatography.¹ The implementation of a continuous process for the metalation steps of the Negishi coupling allowed for the elimination of the cryogenic reaction conditions from the manufacturing process.²



We will also outline improvements to the other key synthesis steps, overall resulting in a 6-fold yield increase and a 29-fold process mass intensity reduction.

- [1] J. Xu, L. Ngiap-Kie, J. Timmerman, J. Shen, K. Clagg, U. Orcel, R. Bigler, E. Trachsel, R. Meier, N. A. White, J. Burkhard, L. E. Sirois, Q. Tian, R. Angelaud, S. Bachmann, H. Zhang, F. Gosselin, *Org. Lett.*, **2023**, *25*, 3417-3422.
- [2] S. M. Kelly, R. Lebl, T. C. Malig, T. Bass, D. Kumkli, D. Kaldre, U. Orcel, L. Tröndlin, D. Linder, J. Sedelmeier, S. Bachmann, C. Han, H. Zhang, F. Gosselin, *Org. Process Res. Dev.* **2024**, *28*, 1546-1555.